Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 20, 2011BloodOpen Access

Dasatinib as first-line treatment for adult patients with Philadelphia chromosome–positive acute lymphoblastic leukemia

View Full Paper
Ask AI
Bookmark
Share

Authors

RFRobin FoàInstitute of Oncology ResearchAVAntonella VitaleUniversity of the Sacred HeartMVMarco VignettiFondazione Gimema Onlus

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Foà et al. (2011) studied this question.

synapsesocial.com/papers/6a85583d8018c50ef23d9a58https://doi.org/10.1182/blood-2011-05-351403
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1A New Method To Evaluate the Prognostic Value of Response to Prednisone Pre-Treatment in Adult (15–60 Yrs) Patients with Acute Lymphoblastic Leukemia: Results of the GIMEMA LAL 2000 Study.2005 · 3 citations
  2. 2Patients' age and BCR-ABL frequency in adult B-precursor ALL: a retrospective analysis from the GMALL study group2008 · 174 citations
  3. 3Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia2010 · 1,602 citations
  4. 4Impact of tyrosine kinase inhibitors on patient outcomes in Philadelphia chromosome‐positive acute lymphoblastic leukaemia2009 · 57 citations
  5. 5A comprehensive genetic classification of adult acute lymphoblastic leukemia (ALL): analysis of the GIMEMA 0496 protocol2005 · 217 citations